Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04368039 · ClinicalTrials.gov registry record · NA
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
A NA study of Schizophrenia and Psychosis, sponsored by Nicholas Breitborde.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04368039: Recruiting NA study of Schizophrenia and Psychosis, sponsored by Nicholas Breitborde.
NCT04368039 is a NA study of Schizophrenia and Psychosis that is actively recruiting participants, run by Nicholas Breitborde. The registered enrollment target is 20 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04368039, a NA study of Schizophrenia and Psychosis, is actively recruiting participants, sponsored by Nicholas Breitborde.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
Primary Outcome
Change in scores on the MATRICS Consensus Cognitive Battery (MCCB).
Conditions Studied
Interventions
- DEVICE Placebo
- DEVICE Normobaric Oxygen
Study Locations (1)
Ohio
- Harding Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-12-04 |
| Est. Completion | 2026-12-07 |
| Phase | NA |
What NCT04368039 shows while recruiting
NCT04368039 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04368039 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04368039 about?
NCT04368039 is a clinical study titled "Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis". Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
What is the current status of trial NCT04368039?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2019-12-04. Estimated completion is 2026-12-07.
What conditions does trial NCT04368039 study?
This clinical trial studies the following conditions: Schizophrenia, Psychosis, First Episode Psychosis.
What interventions are being tested in trial NCT04368039?
The interventions under investigation include: Placebo (DEVICE), Normobaric Oxygen (DEVICE).
Who is sponsoring clinical trial NCT04368039?
This trial is sponsored by Nicholas Breitborde, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04368039 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04368039's enrollment target sits among peer trials
20 286th of 315 higher than 24 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI